Online citations, reference lists, and bibliographies.
← Back to Search

Phase II Trial Of Carboplatin In The Management Of Malignant Mesothelioma.

D. Raghavan, P. Gianoutsos, J. Bishop, J. Lee, I. Young, P. Corté, P. Bye, B. McCaughan
Published 1990 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Thirty-one patients with advanced malignant mesothelioma, previously untreated or having received only one prior cytotoxic regimen, were treated in a prospective, single-arm phase II trial with carboplatin (NSC 241240) at a dose of 150 mg/m2 per day intravenously (IV) for 3 days (450 mg/m2/course). One complete remission and four partial remissions were achieved, yielding an overall objective response rate of 16% (95% confidence interval [CI], 5.4% to 34%). The median duration of remission was 8 months (range, 5 to 17). Nonhematological toxicity was mild (only 12% with World Health Organization [WHO] grade 3 vomiting); 16% suffered WHO grade 3 to 4 hematological toxicity, but there were no life-threatening episodes and no treatment-related deaths. Carboplatin has modest activity against malignant mesothelioma and, because of its low toxicity, has a role in the management of this disease.
This paper references



This paper is referenced by
10.1007/0-387-28274-2_39
First-Line Chemotherapy for Malignant Pleural Mesothelioma
P. Jänne (2005)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1002/cncr.11405
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
10.1111/j.1752-699X.2008.00046.x
Current concepts in chemotherapy for malignant pleural mesothelioma
J. Sørensen (2008)
10.1016/S1556-0864(15)30366-X
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline
P. Ellis (2006)
10.1016/S0169-5002(10)80011-X
Clinical features and current treatment of diffuse malignant pleural mesothelioma.
V. Rusch (1995)
10.1007/978-3-642-76784-5_10
Future Directions in the Therapy of Lung Cancer
J. Bishop (1991)
10.1200/JCO.1996.14.3.1007
Chemotherapy in malignant pleural mesothelioma. A review.
S. T. Ong (1996)
10.1097/JTO.0b013e31818b174d
Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study
G. Hillerdal (2008)
10.1093/ANNONC/MDF663
Pleura mesothelioma: combined modality treatments.
T. Cerny (2002)
10.1007/978-1-4615-1589-0_13
Malignant pleural mesothelioma.
L. Ho (2001)
10.3816/CLC.2009.n.014
Malignant pleural mesothelioma: medical treatment update.
D. Vorobiof (2009)
10.3978/j.issn.2218-6751.2014.07.01
The role of interleukin-6 in malignant mesothelioma.
S. N. Abdul Rahim (2015)
Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.
A. Bakhshandeh (2003)
10.1378/CHEST.116.2.504
Advances in the treatment of malignant pleural mesothelioma.
D. Sterman (1999)
10.1183/09031936.99.13370699
Malignant pleural mesothelioma.
H. Schouwink (1999)
10.5555/URI:PII:009377549290027X
Current experience with high-dose carboplatin therapy.
J. Bishop (1992)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1007/BF00685720
Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group B
N. Vogelzang (2004)
10.1002/(SICI)1097-0142(19970601)79:11<2237::AID-CNCR23>3.0.CO;2-W
Dihydro‐5‐azacytidine in malignant mesothelioma
N. Vogelzang (1997)
Liječenje malignog mezotelioma poplućnice Treatment of malignant pleural mesothelioma
S. Kotarac (2009)
10.1002/cncr.23337
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
10.1002/(SICI)1097-0142(19991115)86:10<1985::AID-CNCR15>3.0.CO;2-H
Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma
H. Kindler (1999)
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura . A phase II study 0
. P. Solheiml (2007)
Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
Mustafa K. Ozvaran (2004)
10.1002/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO;2-Q
Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An italian lung cancer task force (FONICAP) phase II study
A. Ardizzoni (1991)
10.1007/0-387-28274-2_40
Second-Line Chemotherapy
N. Pavlakis (2005)
10.1016/0277-5379(91)90176-E
Intraperitoneal chemotherapy for malignant peritoneal mesothelioma.
L. Vlasveld (1991)
10.1007/3-540-27329-8_9
Chemotherapie des malignen Pleuramesothelioms
S. Tomek (2005)
10.1093/ANNONC/MDI094
Chemotherapy options and new advances in malignant pleural mesothelioma.
J. Steele (2005)
10.1016/S0169-5002(02)00536-6
Ifosfamide, carboplatin and etoposide combined with 41.8 °C whole body hyperthermia for malignant pleural mesothelioma
A. Bakhshandeh (2003)
10.1016/J.LUNGCAN.2006.09.011
Malignant pleural mesothelioma: a new standard of care.
R. Stahel (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar